NKMAX to Treat Autism with SNK... Presentation at International Autism Conference
NKMAX has been selected as an oral presenter for the second consecutive year at the Autism Spectrum Disorder (ASD) conference, the ‘Synchrony Symposium.’
NKMAX’s subsidiary, NKGEN Biotech, announced on the 11th that it will participate in the Synchrony Symposium to present on the correlation between its autologous NK cell therapy (SNK) and autism.
The Synchrony Symposium, an annual event hosted by the BRAIN Foundation, is the only international conference where experts from academia, pharmaceutical, and biotech companies worldwide gather to share diverse research findings on autism. This year, it will be held in California, USA, from the 20th to the 22nd of next month.
NKMAX plans to discuss the function of NK cells in neurodegenerative diseases, particularly autism. It will also present preclinical data on adult patients with progressive neurodegenerative diseases and explore the potential of SNK in autism.
Autism is known to be caused by neuroinflammation triggered by ▲ increased expression of chemokine receptors on abnormally activated CD4+ T cells ▲ disruption of the blood-brain barrier ▲ changes in white and gray matter ▲ abnormal synaptic growth or synaptic density.
Through immune regulatory functions, SNK can identify and eliminate autoreactive CD4+ T cells and damaged neurons in place of regulatory T cells, playing an important role in improving autism and neurodegenerative diseases. In fact, several studies have reported an increase in dysfunctional NK cells with impaired cytotoxic ability and overall immune abnormalities in patients with autism.
Hot Picks Today
"Only Two Per Person" Garbage Bag Crisis Was Just Yesterday... Japan Also Faces Shortage Anxiety
- "Samsung Electronics Employee with 100 Million Won Salary Receiving 600 Million Won Bonus... Estimated Tax Revealed"
- Lived as Family for Over 30 Years... Daughter-in-Law Cast Aside After Husband's Death
- 'Will Demand Finally Decline Due to High Prices?'... "I'll Just Enjoy Nearby Trips" as Japan and China See a Surge
- "Wore It Once, Then This? White Spots All Over 4.15 Million Won Prada Jacket... 'Full Refund Ordered'"
Paul Song, CEO of NKGEN Biotech, stated, “The number of patients with autism is increasing worldwide, and immune dysfunction in autism patients has been reported in various studies. SNK, which applies proprietary patented technology, can activate immunity and significantly contribute to new treatments for autism.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
